Mechanism of resistance to CDK4/6 inhibitors in HR+advanced breast cancer and subsequent treatment strategies
Cyclin-dependent kinase 4/6(CDK4/6)inhibitors plus endocrine therapy have been used as standard first-or second-line treatment for patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer.Although CDK4/6 inhibitors provide excellent control in patients with hormone receptor-positive advanced breast cancer,due to drug resistance cancer progression will eventually occur as treatment proceeds.At present,the resistance mechanism of CDK4/6 inhibitors is not fully understood,and the optimal treatment strategy after failure of CDK4/6 inhibitors remains an urgent problem.This review summarized the potential resistance mechanism and subsequent treatment strategies of CDK4/6 inhibitors.
NETL
NSTL
万方数据
